Here’s a few take-out’s of the half yearly accounts that I...

Here’s a few take-out’s of the half yearly accounts that I thought were interesting, particularly in relation to the positive nature of the language used. I doubt they’d be this positive if they didn’t have confidence in Janssen...?

OPERATIONAL REVIEW

The second half of 2013 commenced with Phylogica announcing an expansion to its collaboration with Janssen after successfully delivering on a major project milestone. As part of this collaboration, Phylogica made significant progress towards validating a technology, referred to as the Endosomal Escape Trap.

This work has SUCCESSFULLY identified a range of novel cell penetrating sequences that were CONFIRMED as having the functional ability to deliver different therapeutic cargoes inside cells.

Having VALIDATED our novel platform to discover functionally active delivery reagents, the company can look forward to translating these findings to commercial outcomes with existing and new Pharma partners.

These features are highly prized in the pharma industry and hence attract significant commercial values.

FINANCIAL STRENGTH

The Company’s cash position is $6.2m, with $0.7m of invoiced revenue and $1.8m from the R&D tax offset = $8.7m. Expenditure is running at the rate of $0.45m giving a CASH RUNWAY OF 19 MONTHS.


OUTLOOK

The Endosomal Escape Trap project has yielded a high quality data-pack that has generated SIGNIFICANT COMMERCIAL INTEREST.

As a result, Phylogica is well positioned to deliver on its objectives over the next 12 months: 1) to drive revenue through discovery alliances; and 2) to establish new out-licensing opportunities by generating value-adding data around its in-house programs.

I’m looking forward to seeing how 2014 pans out, but will be very relieved IF/when the Janssen deal is done.